General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 141: All of the following can cause histamine release except?

A. D-tubocurarine
B. Morphine
C. Propranolol (Correct Answer)
D. Vancomycin

Explanation: **Explanation:** The question tests your knowledge of drugs that cause **non-immunological (direct) histamine release** from mast cells. **1. Why Propranolol is the Correct Answer:** Propranolol is a non-selective beta-blocker. It does not possess the chemical structure or pharmacological property to trigger direct histamine release. In fact, in the context of allergy, beta-blockers are significant because they can **worsen** anaphylaxis and make it resistant to adrenaline, but they do not cause histamine release themselves. **2. Analysis of Incorrect Options:** * **D-tubocurarine:** This skeletal muscle relaxant is a classic example of a drug that causes direct histamine release, often leading to hypotension, flushing, and bronchospasm [1]. * **Morphine:** Opioids (especially morphine and codeine) trigger mast cell degranulation via a non-IgE mediated pathway [1]. This often results in "morphine itch" (pruritus) or urticaria. * **Vancomycin:** This antibiotic is notorious for causing **"Red Man Syndrome"** (or Red Neck Syndrome). This is a rate-dependent infusion reaction caused by direct histamine release, characterized by intense flushing of the upper body. **3. NEET-PG High-Yield Clinical Pearls:** * **Direct Histamine Releasers (Mnemonic: "M-A-V-E-D"):** **M**orphine, **A**mphotericin B, **V**ancomycin, **E**pinephrine (rarely), **D**-tubocurarine/Radiocontrast media [1]. * **Red Man Syndrome Prevention:** Slow the infusion rate of Vancomycin (administer over at least 60 minutes) and/or pre-treat with antihistamines. * **Clinical Sign:** Direct histamine release usually causes localized or systemic flushing, hypotension, and pruritus, but unlike true Type I hypersensitivity, it is not IgE-mediated and often depends on the dose or rate of administration [1].

Question 142: What is the site of action of vecuronium?

A. Cerebrum
B. Reticular formation
C. Motor neuron
D. Myoneural junction (Correct Answer)

Explanation: **Explanation:** **Vecuronium** is a non-depolarizing neuromuscular blocking agent (NMBA) belonging to the aminosteroid group. **1. Why the Correct Answer is Right:** The primary site of action for vecuronium is the **myoneural junction** (also known as the neuromuscular junction or NMJ). It acts as a competitive antagonist at the **nicotinic acetylcholine receptors (Nm)** located on the post-junctional motor endplate. By binding to these receptors, vecuronium prevents acetylcholine from triggering depolarization, thereby leading to flaccid skeletal muscle paralysis. **2. Why the Other Options are Incorrect:** * **Cerebrum & Reticular Formation (Options A & B):** Vecuronium is a quaternary ammonium compound, making it highly polar and lipid-insoluble. Consequently, it **cannot cross the blood-brain barrier (BBB)**. It has no effect on the Central Nervous System (CNS), meaning it provides no sedation or analgesia. * **Motor Neuron (Option C):** Vecuronium does not inhibit the electrical conduction along the nerve axon or the release of acetylcholine from the pre-synaptic terminal; its action is strictly post-synaptic at the muscle endplate. **3. Clinical Pearls for NEET-PG:** * **Metabolism:** It is primarily excreted via **bile** (undergoes hepatic metabolism), making it safer than pancuronium in renal failure, though caution is still advised. * **Cardiovascular Stability:** Unlike tubocurarine or pancuronium, vecuronium has minimal histamine release and lacks significant vagolytic effects, ensuring high cardiovascular stability. * **Reversal:** Its effects can be reversed using acetylcholinesterase inhibitors (e.g., **Neostigmine**) or the specific chelating agent **Sugammadex**. * **Intermediate Acting:** It has an intermediate duration of action (approx. 30–40 minutes).

Question 143: What is acute or rapidly developing tolerance to a drug?

A. Anaphylaxis
B. Teratogenic effects (Correct Answer)
C. Induction
D. Supersensitivity

Explanation: **Explanation:** The question asks for the term describing acute or rapidly developing tolerance. In pharmacology, this phenomenon is known as **Tachyphylaxis**. **Note on the provided options:** There appears to be a discrepancy in the provided key. **Tachyphylaxis** is the standard medical term for rapid tolerance. However, based on the options provided: 1. **Correct Concept (Tachyphylaxis):** It occurs when repeated doses of a drug at short intervals lead to a rapid decrease in pharmacological response (e.g., Ephedrine, Tyramine, or Nicotine). This is often due to the depletion of neurotransmitter stores or receptor desensitization. 2. **Why "Teratogenic effects" is marked (Contextual Note):** In some older question banks or specific exam patterns, if "Tachyphylaxis" is missing, students must identify the error. However, strictly speaking, **Teratogenicity** refers to fetal abnormalities caused by drugs (e.g., Thalidomide) and is **not** a form of tolerance. **Analysis of Options:** * **A. Anaphylaxis:** An exaggerated IgE-mediated Type I hypersensitivity reaction; it is an allergic response, not tolerance. * **B. Teratogenic effects:** Refers to structural or functional defects in the developing fetus. (Clinically incorrect as a definition for rapid tolerance). * **C. Induction (Enzyme Induction):** This refers to a drug increasing the synthesis of CYP450 enzymes, leading to faster metabolism of drugs over weeks, not acute tolerance. * **D. Supersensitivity:** An increased response to a drug, often following denervation or prolonged use of antagonists (the opposite of tolerance). **High-Yield NEET-PG Pearls:** * **Tachyphylaxis Examples:** Ephedrine (displacement of NA), Tyramine, Nitroglycerin (depletion of -SH groups), and Hydralazine. * **Tolerance vs. Tachyphylaxis:** Tolerance is gradual (days/weeks); Tachyphylaxis is instantaneous/acute (minutes/hours). * **Mechanism:** Often involves receptor down-regulation or exhaustion of mediators.

Question 144: Which of the following is calculated as the ratio of the area under the curve (AUC) obtained by oral administration versus the AUC for intravenous administration of the same drug?

A. Absorption
B. Bioavailability (Correct Answer)
C. Clearance
D. Elimination rate constant

Explanation: **Explanation:** **1. Why Bioavailability is Correct:** Bioavailability ($F$) is defined as the fraction of an administered dose of unchanged drug that reaches the systemic circulation. When a drug is given intravenously (IV), its bioavailability is 100% ($F=1$). For other routes (like oral), bioavailability is calculated by comparing the **Area Under the Curve (AUC)**—which represents the total drug exposure over time—of the oral dose to the AUC of the IV dose. The formula is: $$F = \frac{AUC_{\text{oral}}}{AUC_{\text{IV}}} \times \frac{\text{Dose}_{\text{IV}}}{\text{Dose}_{\text{oral}}}$$ If the doses are equal, it is simply the ratio of $AUC_{\text{oral}} / AUC_{\text{IV}}$. **2. Why Other Options are Incorrect:** * **Absorption (A):** While bioavailability depends on absorption, they are not synonymous. Absorption refers to the movement of a drug from its site of administration into the blood, whereas bioavailability also accounts for **first-pass metabolism** in the gut wall and liver. * **Clearance (C):** This is the volume of plasma cleared of the drug per unit of time ($CL = \text{Rate of elimination} / \text{Plasma concentration}$). It relates to the removal of the drug, not its entry into circulation. * **Elimination Rate Constant (D):** This ($k_e$) represents the fraction of drug removed per unit of time. It is calculated as $CL / V_d$ (Volume of Distribution). **3. High-Yield Clinical Pearls for NEET-PG:** * **First-Pass Effect:** High first-pass metabolism (e.g., Nitroglycerin, Propranolol, Morphine) significantly reduces oral bioavailability. * **Bioequivalence:** Two pharmaceutical products are bioequivalent if their rates and extents of bioavailability do not show a significant difference when administered at the same molar dose. * **AUC** is the most reliable measure of the **extent** of bioavailability, while **$C_{max}$** (peak plasma concentration) and **$T_{max}$** (time to reach $C_{max}$) reflect the **rate** of absorption.

Question 145: FK-506 is a

A. macrolide antibiotic (Correct Answer)
B. Immunoglobulin antibody
C. Non-depolarizing muscle relaxant
D. Opioid analgesic

Explanation: **Explanation:** **FK-506**, commonly known as **Tacrolimus**, is a potent immunosuppressant. Chemically, it is classified as a **macrolide antibiotic** (Option A) because it contains a large macrocyclic lactone ring in its structure. Although it shares a structural class with antibiotics like Erythromycin, it lacks significant antibacterial activity and is used exclusively for its immunosuppressive properties. **Mechanism of Action:** Tacrolimus acts as a **Calcineurin Inhibitor**. It binds to an intracellular protein called **FK-binding protein (FKBP-12)**. This complex inhibits calcineurin, preventing the dephosphorylation of the Nuclear Factor of Activated T-cells (NFAT). Consequently, the transcription of **Interleukin-2 (IL-2)** is blocked, inhibiting T-lymphocyte activation. **Analysis of Incorrect Options:** * **Option B:** It is a small molecule drug, not a protein-based immunoglobulin or monoclonal antibody. * **Option C:** It has no effect on the neuromuscular junction; examples of non-depolarizing relaxants include Vecuronium or Atracurium. * **Option D:** It does not act on opioid receptors; examples include Morphine or Fentanyl. **High-Yield Clinical Pearls for NEET-PG:** * **Potency:** Tacrolimus is 10–100 times more potent than Cyclosporine. * **Indications:** Preferred drug for preventing organ rejection in liver, kidney, and heart transplants; also used topically for atopic dermatitis. * **Side Effects:** Nephrotoxicity (most common), neurotoxicity (tremors, seizures), and **new-onset diabetes after transplantation (NODAT)**. * **Comparison:** Unlike Cyclosporine, Tacrolimus does **not** typically cause hirsutism or gum hyperplasia.

Question 146: A widely used drug that suppresses cellular immunity, inhibits prostaglandin and leukotriene synthesis, and increases the catabolism of IgG antibody is:

A. Cyclophosphamide
B. Prednisone (Correct Answer)
C. Cyclosporine
D. Infliximab

Explanation: ### Explanation **Correct Option: B. Prednisone** **Mechanism of Action:** Prednisone is a corticosteroid that exerts broad immunosuppressive and anti-inflammatory effects through multiple pathways: 1. **Suppression of Cellular Immunity:** It inhibits the production of IL-2 and other cytokines, leading to decreased T-cell proliferation and recruitment. 2. **Inhibition of Eicosanoids:** It induces **Lipocortin (Annexin A1)**, which inhibits the enzyme **Phospholipase A2**. This prevents the release of arachidonic acid, thereby blocking the synthesis of both **prostaglandins** (via COX pathway) and **leukotrienes** (via LOX pathway). 3. **IgG Catabolism:** Corticosteroids are unique among immunosuppressants for their ability to increase the fractional catabolic rate of IgG antibodies, reducing their serum concentration. --- ### Why Other Options are Incorrect: * **A. Cyclophosphamide:** An alkylating agent that primarily acts by cross-linking DNA. While it suppresses B-cell and T-cell function, it does not directly inhibit Phospholipase A2 or increase IgG catabolism. * **C. Cyclosporine:** A calcineurin inhibitor that specifically inhibits IL-2 production. It focuses on T-cell suppression but does not inhibit the synthesis of prostaglandins or leukotrienes. * **D. Infliximab:** A monoclonal antibody that specifically neutralizes **TNF-α**. It does not have a broad effect on eicosanoid synthesis or antibody catabolism. --- ### NEET-PG High-Yield Pearls: * **Steroid-induced Leukocytosis:** Glucocorticoids cause an increase in Neutrophils (due to decreased marginalization) but a decrease in Lymphocytes, Eosinophils, and Monocytes. * **Metabolic Effects:** Remember the mnemonic **"S"** for Steroids: **S**ugar increases (Hyperglycemia), **S**alt increases (Hypernatremia/Edema), and **S**ex hormones decrease (Adrenal suppression). * **Drug of Choice:** Prednisone is a mainstay in treating autoimmune conditions like SLE and preventing graft-versus-host disease (GVHD).

Question 147: Secukinumab is:

A. Anti IL-1
B. Anti IL-6
C. Anti IL-17 (Correct Answer)
D. Anti IL-23

Explanation: **Explanation:** **Secukinumab** is a high-affinity recombinant human monoclonal antibody that selectively binds to and neutralizes **Interleukin-17A (IL-17A)**. IL-17 is a pro-inflammatory cytokine produced primarily by Th17 cells; it plays a critical role in the pathogenesis of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis by inducing the production of chemokines and mediators of tissue inflammation. **Analysis of Options:** * **Option A (Anti IL-1):** Drugs targeting IL-1 include **Anakinra** (IL-1 receptor antagonist), **Canakinumab**, and **Rilonacept**. These are primarily used in cryopyrin-associated periodic syndromes (CAPS) and refractory Rheumatoid Arthritis. * **Option B (Anti IL-6):** **Tocilizumab** and **Sarilumab** are the classic IL-6 receptor antagonists used in Rheumatoid Arthritis and Giant Cell Arteritis. * **Option C (Correct):** Secukinumab (along with Ixekizumab) targets IL-17A. Brodalumab is another related drug that targets the IL-17 receptor. * **Option D (Anti IL-23):** Drugs targeting the p40 subunit of IL-12/23 include **Ustekinumab**, while **Guselkumab** and **Risankizumab** specifically target IL-23. **High-Yield Clinical Pearls for NEET-PG:** * **Indications:** Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. * **Side Effects:** Increased risk of infections (especially upper respiratory tract) and a notable association with **Mucocutaneous Candidiasis** (since IL-17 is essential for host defense against fungi). * **Contraindication:** It may exacerbate **Inflammatory Bowel Disease (IBD)**, so it should be avoided in patients with Crohn’s disease or Ulcerative Colitis.

Question 148: Most essential medicines should be formulated as which of the following?

A. No compound
B. Single compound (Correct Answer)
C. Multiple compounds
D. Fixed dose combinations

Explanation: **Explanation:** The concept of **Essential Medicines**, as defined by the WHO, refers to those drugs that satisfy the priority healthcare needs of the population. According to the WHO Model List of Essential Medicines, most essential medicines should be formulated as **single compounds**. **1. Why Single Compound is Correct:** * **Flexibility in Dosing:** Single compounds allow clinicians to adjust the dose of a specific drug according to the patient's individual needs (e.g., age, renal function, or weight). * **Safety and Monitoring:** If an adverse drug reaction occurs, it is easier to identify the causative agent when drugs are administered separately. * **Cost-Effectiveness:** Single-ingredient formulations are generally cheaper to manufacture and procure in bulk for national health programs. * **Reduced Resistance:** In the case of antibiotics, using single agents (unless synergy is required) helps prevent the development of multi-drug resistance. **2. Why Other Options are Incorrect:** * **Fixed-Dose Combinations (FDCs):** While FDCs improve patient compliance (e.g., in TB or HIV treatment), they are generally discouraged as a rule for essential medicines because they offer no flexibility in adjusting individual drug doses and may lead to unnecessary exposure to a drug the patient doesn't need. * **Multiple Compounds:** This is synonymous with non-fixed combinations, which complicates pharmacy inventory and increases the risk of drug-drug interactions if not monitored. * **No Compound:** This is clinically irrelevant as a formulation strategy. **Clinical Pearls for NEET-PG:** * **WHO Definition:** Essential medicines are selected based on disease prevalence, safety, efficacy, and comparative cost-effectiveness. * **P-Drugs (Personal Drugs):** These are drugs chosen by a practitioner to be used regularly in their practice, based on the essential medicine concept. * **FDC Criteria:** An FDC is only considered "essential" if the combination has a proven advantage over single compounds administered separately (e.g., Levodopa + Carbidopa).

Question 149: Sir Alexander Fleming received the Nobel Prize for which discovery?

A. Insulin
B. CT scan
C. Penicillin (Correct Answer)
D. ECG

Explanation: Explanation: Correct Answer: C. Penicillin Sir Alexander Fleming, a Scottish bacteriologist, discovered Penicillin in 1928 at St. Mary's Hospital, London [2]. He observed that the mold Penicillium notatum produced a substance that inhibited the growth of Staphylococcus aureus [2]. This discovery ushered in the "Antibiotic Era." For this monumental achievement, Fleming shared the Nobel Prize in Physiology or Medicine in 1945 with Howard Florey and Ernst Chain, who were instrumental in the mass production and clinical application of the drug [1], [4]. Analysis of Incorrect Options: * A. Insulin: Discovered by Frederick Banting and Charles Best in 1921 [3]. Banting and John Macleod received the Nobel Prize for this in 1923. * B. CT scan: Developed by Godfrey Hounsfield and Allan Cormack, who shared the Nobel Prize in 1979. * D. ECG: The first practical electrocardiogram was developed by Willem Einthoven in 1903, for which he received the Nobel Prize in 1924. High-Yield Clinical Pearls for NEET-PG: * Mechanism of Action: Penicillin is a Beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to Penicillin-Binding Proteins (PBPs), preventing the cross-linking of peptidoglycan. * Source: Originally derived from Penicillium notatum (now P. chrysogenum) [1], [2]. * Serendipity: Fleming’s discovery is a classic example of "serendipity" (accidental discovery) in pharmacology [2]. * Resistance: The most common mechanism of resistance against Penicillins is the production of Beta-lactamase enzymes by bacteria.

Question 150: A farmer presented in the OPD clinic with sweating, lacrimation, and pinpoint pupils. What type of poisoning is suspected?

A. Dhatura poisoning
B. Organophosphate poisoning (Correct Answer)
C. Atropine poisoning
D. Cocaine poisoning

Explanation: **Explanation:** The clinical presentation of **sweating, lacrimation, and pinpoint pupils (miosis)** represents a classic **Cholinergic Toxidrome**. This occurs due to the excessive accumulation of acetylcholine at the synaptic cleft, leading to overstimulation of muscarinic and nicotinic receptors [1]. **Why Organophosphate (OP) Poisoning is Correct:** Organophosphates are irreversible inhibitors of the enzyme **Acetylcholinesterase** [3]. In a rural setting, a farmer is frequently exposed to these compounds via pesticides [1], [4]. The symptoms follow the **DUMBELS** mnemonic: Diarrhea, Urination, Miosis, Bradycardia/Bronchospasm, Emesis, Lacrimation, and Salivation/Sweating [1]. The presence of pinpoint pupils and excessive secretions is pathognomonic for OP poisoning. **Why Other Options are Incorrect:** * **Dhatura and Atropine Poisoning:** These are **Anticholinergic** agents. They present with the exact opposite symptoms: dry skin (no sweating), dry mouth, and **mydriasis** (dilated pupils). The classic description is "Dry as a bone, Red as a beet, Blind as a bat, Mad as a hatter." * **Cocaine Poisoning:** Cocaine is a sympathomimetic stimulant. It causes **mydriasis** (dilated pupils) due to increased sympathetic activity, along with tachycardia and hypertension [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Management:** The specific antidote is **Atropine** (to reverse muscarinic effects) and **Pralidoxime (2-PAM)** (to regenerate cholinesterase, must be given before "aging" of the enzyme occurs) [5]. * **Monitoring:** The adequacy of atropinization is best monitored by the **drying of pulmonary secretions** and an increase in heart rate, rather than pupil size alone. * **Diagnosis:** Confirmed by measuring **Red Blood Cell (RBC) cholinesterase levels**, which is more specific than plasma cholinesterase.

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free